Riverain Technologies’ Global Healthcare Innovation Expands

Riverain Technologies’ Global Healthcare Innovation Expands

In a groundbreaking development for medical imaging technology, Riverain Technologies has marked an exceptional year of growth and innovation. The company’s expansion across eight countries in 2024, coupled with the addition of nearly 50 new customers, showcases the increasing global demand for advanced cardiothoracic disease detection solutions.

Revolutionary Advancement in Cardiac Screening

Building on its impressive 147% growth in 2024, Riverain Technologies has introduced FDA-cleared technology that revolutionizes coronary heart disease detection. This innovative advancement extends ClearRead CT functionality by enabling coronary artery calcium (CAC) scoring for ungated scans without contrast, facilitating opportunistic screening for the world’s leading cause of death.

Clinical Validation and Efficiency Gains

A landmark study conducted by the University of Washington School of Medicine has validated the effectiveness of ClearRead CT Vessel Suppression technology. The research, presented at the 2024 RSNA annual meeting, demonstrated a remarkable 36% reduction in radiologists’ reading times for pulmonary nodule identification, highlighting the technology’s significant impact on clinical workflow efficiency.

Global Market Expansion and Strategic Partnerships

The company’s strategic expansion has brought ClearRead technology to medical professionals across diverse geographic regions, including New Zealand, Australia, Saudi Arabia, Spain, United Kingdom, South Africa, Italy, and Belgium. A notable partnership with RevealDX in Canada has integrated malignancy prediction score technology, enhancing radiologists’ ability to make informed follow-up recommendations.

Strengthening Healthcare Infrastructure

Riverain’s commitment to improving healthcare delivery is evident in its expanded presence within VA medical centers, now serving 104 sites nationally after adding 52 new locations in 2024. The company has also experienced exceptional channel partner growth, reporting a 240% year-over-year increase in activity.

Revolutionary Growth in Global Healthcare Markets

Riverain Technologies has achieved remarkable expansion, establishing its presence in eight new countries including New Zealand, Australia, Saudi Arabia, Spain, United Kingdom, South Africa, Italy, and Belgium. This strategic growth has resulted in partnerships with nearly 50 new healthcare facilities, demonstrating the increasing global demand for advanced medical imaging solutions.

Industry Leadership and Educational Initiatives

Throughout 2024, Riverain maintained a strong presence at leading industry events, including:

• The Radiological Society of North America annual meeting
• European Congress of Radiology
• Society of Thoracic Radiology annual meeting
• Southern Radiological Show
• American Cancer Society conferences
• The Chest Show
• American Association for Bronchology and Interventional Pulmonology

Innovation in Training and Support

Recognizing the importance of user proficiency, Riverain has launched a virtual applications training platform to support its rapidly expanding global customer base. This initiative ensures healthcare providers can maximize the benefits of ClearRead technology regardless of their location.

Groundbreaking FDA-Cleared Technology

The company’s latest innovation centers on FDA-cleared technology that enhances ClearRead CT functionality. This advancement enables healthcare providers to obtain coronary artery calcium (CAC) scores from ungated scans without contrast, representing a significant breakthrough in cardiac health assessment. This development is particularly crucial given that coronary heart disease remains the leading cause of mortality both in the United States and globally.

Advanced Diagnostic Capabilities

ClearRead CT and ClearRead Xray with Clear Visual Intelligence represent the culmination of Riverain’s commitment to diagnostic excellence. These patented, workflow-friendly solutions provide clinicians with an unobstructed view of the chest, accompanied by tools that enhance efficiency, accuracy, and detection capabilities. The comprehensive suite includes:

• Nodule detection with volumetric analysis
• CAC quantification
• Portable line and tube enhancement
• Pneumothorax alerts

Steve Worrell, CEO of Riverain Technologies, emphasizes the global impact: “Radiologists worldwide are seeing the value of our technology to help improve reading speed and accuracy. Our 2024 growth was driven by strong product market acceptance through network effects.”

The continued expansion and innovation demonstrated by Riverain Technologies underscore its position as a leader in medical imaging technology, with a clear focus on improving patient care through advanced diagnostic solutions.

Discover the latest Provider news updates with a single click. Follow DistilINFO HospitalIT and stay ahead with updates. Join our community today!